Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision: v3.3.4 added, replacing the previous v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedLocations sections for Alberta, New Brunswick, and Ontario have been added under the Study Locations, and the prior provincial location subsections have been removed. The page revision tag has been updated to v3.3.3.SummaryDifference0.4%

- Check57 days agoChange DetectedThe Publications section now includes a note that items are automatically filled from PubMed. The revision tag updates from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check65 days agoChange DetectedThe government funding lapse notice has been removed from the page, and this does not affect the study details or core content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check86 days agoChange DetectedSubstantive study details (eligibility criteria, interventions, primary/secondary outcomes, and locations) appear unchanged. Minor formatting differences observed do not affect the content.SummaryDifference0.4%

- Check108 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.